Research ArticleArticle
Safety and Effectiveness of 6 Months' Etanercept Monotherapy and Combination Therapy in Japanese Patients with Rheumatoid Arthritis: Effect of Concomitant Disease-modifying Antirheumatic Drugs
Takao Koike, Masayoshi Harigai, Shigeko Inokuma, Naoki Ishiguro, Junnosuke Ryu, Tsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka, Tomohiro Hirose, Takunari Yoshinaga and Michio Suzukawa
The Journal of Rheumatology August 2013, jrheum.120490; DOI: https://doi.org/10.3899/jrheum.120490
Takao Koike
From the NTT Sapporo Medical Center, Sapporo; Tokyo Medical Dental University Graduate School, Tokyo; Japanese Red Cross Medical Center, Tokyo; Nagoya University Graduate School of Medicine, Nagoya; Nihon University School of Medicine, Tokyo; Keio University, Tokyo; University of Occupational and Environmental Health, Kitakyushu; Tokyo Women’s Medical University, Tokyo; Pfizer Japan Inc., Medical Affairs, and Postmarketing Surveillance, Tokyo, Japan. Supported by Wyeth; clinical fees were shared by Wyeth K.K. and Takeda Pharmaceutical Company Ltd. T. Koike, M. Harigai, S. Inokuma, N. Ishiguro, J. Ryu, T. Takeuchi, Y. Tanaka, and H. Yamanaka are all members of the Etanercept Postmarketing Surveillance Committee of the Japan College of Rheumatology. Financial relationships of authors with all manufacturers of products used in the management of rheumatoid arthritis are as follows. T. Koike: consulting fee from UCB Japan Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Takeda Pharmaceutical Co. Ltd., Pfizer Japan Inc. M. Harigai: research grant to the affiliated institution from AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; consulting fee from AbbVie G.K., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp.; on the speakers’ bureau of AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. S. Inokuma: none. N. Ishiguro: research grant to the affiliated institution from Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. J. Ryu: none. T. Takeuchi: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Sanofi K.K., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; consulting fee from AbbVie G.K., Asahi Kasei Pharma Corp., AstraZeneca K.K., Daiichi Sankyo Co. Ltd., Eli-Lilly Japan K.K., Mitsubishi Tanabe Pharma Corp., Novartis Pharma K.K.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. Y. Tanaka: research grant to the affiliated institution from AbbVie G.K., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., MSD; on the speakers’ bureau of AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Pfizer Japan Inc., Quintiles Inc., Takeda Pharmaceutical Co. Ltd. H. Yamanaka: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Nippon Kayaku Co. Ltd., Pfizer Japan Inc., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd. T. Hirose, T. Yoshinaga, and M. Suzukawa are fulltime employees of Pfizer Japan Inc. T. Koike, MD, PhD, NTT Sapporo Medical Center; M. Harigai, MD, PhD, Tokyo Medical Dental University Graduate School; S. Inokuma, MD, Japanese Red Cross Medical Center; N. Ishiguro, MD, PhD, Nagoya University Graduate School of Medicine; J. Ryu, MD, PhD, Nihon University School of Medicine; T. Takeuchi, MD, PhD, Keio University; Y. Tanaka, MD, PhD, University of Occupational and Environmental Health; H. Yamanaka, MD, PhD, Tokyo Women’s Medical University; T. Hirose, MS, Pfizer Japan Inc., Medical Affairs; T. Yoshinaga, MD, PhD, Pfizer Japan Inc., Postmarketing Surveillance; M. Suzukawa, MD, PhD, Pfizer Japan Inc., Medical Affairs. Address correspondence to Dr. T. Yoshinaga, MD, PhD, Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan. E-mail: takunari.yoshinaga@pfizer.com Accepted for publication June 6, 2013.
Masayoshi Harigai
From the NTT Sapporo Medical Center, Sapporo; Tokyo Medical Dental University Graduate School, Tokyo; Japanese Red Cross Medical Center, Tokyo; Nagoya University Graduate School of Medicine, Nagoya; Nihon University School of Medicine, Tokyo; Keio University, Tokyo; University of Occupational and Environmental Health, Kitakyushu; Tokyo Women’s Medical University, Tokyo; Pfizer Japan Inc., Medical Affairs, and Postmarketing Surveillance, Tokyo, Japan. Supported by Wyeth; clinical fees were shared by Wyeth K.K. and Takeda Pharmaceutical Company Ltd. T. Koike, M. Harigai, S. Inokuma, N. Ishiguro, J. Ryu, T. Takeuchi, Y. Tanaka, and H. Yamanaka are all members of the Etanercept Postmarketing Surveillance Committee of the Japan College of Rheumatology. Financial relationships of authors with all manufacturers of products used in the management of rheumatoid arthritis are as follows. T. Koike: consulting fee from UCB Japan Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Takeda Pharmaceutical Co. Ltd., Pfizer Japan Inc. M. Harigai: research grant to the affiliated institution from AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; consulting fee from AbbVie G.K., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp.; on the speakers’ bureau of AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. S. Inokuma: none. N. Ishiguro: research grant to the affiliated institution from Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. J. Ryu: none. T. Takeuchi: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Sanofi K.K., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; consulting fee from AbbVie G.K., Asahi Kasei Pharma Corp., AstraZeneca K.K., Daiichi Sankyo Co. Ltd., Eli-Lilly Japan K.K., Mitsubishi Tanabe Pharma Corp., Novartis Pharma K.K.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. Y. Tanaka: research grant to the affiliated institution from AbbVie G.K., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., MSD; on the speakers’ bureau of AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Pfizer Japan Inc., Quintiles Inc., Takeda Pharmaceutical Co. Ltd. H. Yamanaka: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Nippon Kayaku Co. Ltd., Pfizer Japan Inc., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd. T. Hirose, T. Yoshinaga, and M. Suzukawa are fulltime employees of Pfizer Japan Inc. T. Koike, MD, PhD, NTT Sapporo Medical Center; M. Harigai, MD, PhD, Tokyo Medical Dental University Graduate School; S. Inokuma, MD, Japanese Red Cross Medical Center; N. Ishiguro, MD, PhD, Nagoya University Graduate School of Medicine; J. Ryu, MD, PhD, Nihon University School of Medicine; T. Takeuchi, MD, PhD, Keio University; Y. Tanaka, MD, PhD, University of Occupational and Environmental Health; H. Yamanaka, MD, PhD, Tokyo Women’s Medical University; T. Hirose, MS, Pfizer Japan Inc., Medical Affairs; T. Yoshinaga, MD, PhD, Pfizer Japan Inc., Postmarketing Surveillance; M. Suzukawa, MD, PhD, Pfizer Japan Inc., Medical Affairs. Address correspondence to Dr. T. Yoshinaga, MD, PhD, Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan. E-mail: takunari.yoshinaga@pfizer.com Accepted for publication June 6, 2013.
Shigeko Inokuma
From the NTT Sapporo Medical Center, Sapporo; Tokyo Medical Dental University Graduate School, Tokyo; Japanese Red Cross Medical Center, Tokyo; Nagoya University Graduate School of Medicine, Nagoya; Nihon University School of Medicine, Tokyo; Keio University, Tokyo; University of Occupational and Environmental Health, Kitakyushu; Tokyo Women’s Medical University, Tokyo; Pfizer Japan Inc., Medical Affairs, and Postmarketing Surveillance, Tokyo, Japan. Supported by Wyeth; clinical fees were shared by Wyeth K.K. and Takeda Pharmaceutical Company Ltd. T. Koike, M. Harigai, S. Inokuma, N. Ishiguro, J. Ryu, T. Takeuchi, Y. Tanaka, and H. Yamanaka are all members of the Etanercept Postmarketing Surveillance Committee of the Japan College of Rheumatology. Financial relationships of authors with all manufacturers of products used in the management of rheumatoid arthritis are as follows. T. Koike: consulting fee from UCB Japan Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Takeda Pharmaceutical Co. Ltd., Pfizer Japan Inc. M. Harigai: research grant to the affiliated institution from AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; consulting fee from AbbVie G.K., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp.; on the speakers’ bureau of AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. S. Inokuma: none. N. Ishiguro: research grant to the affiliated institution from Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. J. Ryu: none. T. Takeuchi: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Sanofi K.K., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; consulting fee from AbbVie G.K., Asahi Kasei Pharma Corp., AstraZeneca K.K., Daiichi Sankyo Co. Ltd., Eli-Lilly Japan K.K., Mitsubishi Tanabe Pharma Corp., Novartis Pharma K.K.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. Y. Tanaka: research grant to the affiliated institution from AbbVie G.K., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., MSD; on the speakers’ bureau of AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Pfizer Japan Inc., Quintiles Inc., Takeda Pharmaceutical Co. Ltd. H. Yamanaka: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Nippon Kayaku Co. Ltd., Pfizer Japan Inc., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd. T. Hirose, T. Yoshinaga, and M. Suzukawa are fulltime employees of Pfizer Japan Inc. T. Koike, MD, PhD, NTT Sapporo Medical Center; M. Harigai, MD, PhD, Tokyo Medical Dental University Graduate School; S. Inokuma, MD, Japanese Red Cross Medical Center; N. Ishiguro, MD, PhD, Nagoya University Graduate School of Medicine; J. Ryu, MD, PhD, Nihon University School of Medicine; T. Takeuchi, MD, PhD, Keio University; Y. Tanaka, MD, PhD, University of Occupational and Environmental Health; H. Yamanaka, MD, PhD, Tokyo Women’s Medical University; T. Hirose, MS, Pfizer Japan Inc., Medical Affairs; T. Yoshinaga, MD, PhD, Pfizer Japan Inc., Postmarketing Surveillance; M. Suzukawa, MD, PhD, Pfizer Japan Inc., Medical Affairs. Address correspondence to Dr. T. Yoshinaga, MD, PhD, Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan. E-mail: takunari.yoshinaga@pfizer.com Accepted for publication June 6, 2013.
Naoki Ishiguro
From the NTT Sapporo Medical Center, Sapporo; Tokyo Medical Dental University Graduate School, Tokyo; Japanese Red Cross Medical Center, Tokyo; Nagoya University Graduate School of Medicine, Nagoya; Nihon University School of Medicine, Tokyo; Keio University, Tokyo; University of Occupational and Environmental Health, Kitakyushu; Tokyo Women’s Medical University, Tokyo; Pfizer Japan Inc., Medical Affairs, and Postmarketing Surveillance, Tokyo, Japan. Supported by Wyeth; clinical fees were shared by Wyeth K.K. and Takeda Pharmaceutical Company Ltd. T. Koike, M. Harigai, S. Inokuma, N. Ishiguro, J. Ryu, T. Takeuchi, Y. Tanaka, and H. Yamanaka are all members of the Etanercept Postmarketing Surveillance Committee of the Japan College of Rheumatology. Financial relationships of authors with all manufacturers of products used in the management of rheumatoid arthritis are as follows. T. Koike: consulting fee from UCB Japan Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Takeda Pharmaceutical Co. Ltd., Pfizer Japan Inc. M. Harigai: research grant to the affiliated institution from AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; consulting fee from AbbVie G.K., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp.; on the speakers’ bureau of AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. S. Inokuma: none. N. Ishiguro: research grant to the affiliated institution from Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. J. Ryu: none. T. Takeuchi: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Sanofi K.K., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; consulting fee from AbbVie G.K., Asahi Kasei Pharma Corp., AstraZeneca K.K., Daiichi Sankyo Co. Ltd., Eli-Lilly Japan K.K., Mitsubishi Tanabe Pharma Corp., Novartis Pharma K.K.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. Y. Tanaka: research grant to the affiliated institution from AbbVie G.K., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., MSD; on the speakers’ bureau of AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Pfizer Japan Inc., Quintiles Inc., Takeda Pharmaceutical Co. Ltd. H. Yamanaka: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Nippon Kayaku Co. Ltd., Pfizer Japan Inc., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd. T. Hirose, T. Yoshinaga, and M. Suzukawa are fulltime employees of Pfizer Japan Inc. T. Koike, MD, PhD, NTT Sapporo Medical Center; M. Harigai, MD, PhD, Tokyo Medical Dental University Graduate School; S. Inokuma, MD, Japanese Red Cross Medical Center; N. Ishiguro, MD, PhD, Nagoya University Graduate School of Medicine; J. Ryu, MD, PhD, Nihon University School of Medicine; T. Takeuchi, MD, PhD, Keio University; Y. Tanaka, MD, PhD, University of Occupational and Environmental Health; H. Yamanaka, MD, PhD, Tokyo Women’s Medical University; T. Hirose, MS, Pfizer Japan Inc., Medical Affairs; T. Yoshinaga, MD, PhD, Pfizer Japan Inc., Postmarketing Surveillance; M. Suzukawa, MD, PhD, Pfizer Japan Inc., Medical Affairs. Address correspondence to Dr. T. Yoshinaga, MD, PhD, Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan. E-mail: takunari.yoshinaga@pfizer.com Accepted for publication June 6, 2013.
Junnosuke Ryu
From the NTT Sapporo Medical Center, Sapporo; Tokyo Medical Dental University Graduate School, Tokyo; Japanese Red Cross Medical Center, Tokyo; Nagoya University Graduate School of Medicine, Nagoya; Nihon University School of Medicine, Tokyo; Keio University, Tokyo; University of Occupational and Environmental Health, Kitakyushu; Tokyo Women’s Medical University, Tokyo; Pfizer Japan Inc., Medical Affairs, and Postmarketing Surveillance, Tokyo, Japan. Supported by Wyeth; clinical fees were shared by Wyeth K.K. and Takeda Pharmaceutical Company Ltd. T. Koike, M. Harigai, S. Inokuma, N. Ishiguro, J. Ryu, T. Takeuchi, Y. Tanaka, and H. Yamanaka are all members of the Etanercept Postmarketing Surveillance Committee of the Japan College of Rheumatology. Financial relationships of authors with all manufacturers of products used in the management of rheumatoid arthritis are as follows. T. Koike: consulting fee from UCB Japan Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Takeda Pharmaceutical Co. Ltd., Pfizer Japan Inc. M. Harigai: research grant to the affiliated institution from AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; consulting fee from AbbVie G.K., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp.; on the speakers’ bureau of AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. S. Inokuma: none. N. Ishiguro: research grant to the affiliated institution from Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. J. Ryu: none. T. Takeuchi: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Sanofi K.K., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; consulting fee from AbbVie G.K., Asahi Kasei Pharma Corp., AstraZeneca K.K., Daiichi Sankyo Co. Ltd., Eli-Lilly Japan K.K., Mitsubishi Tanabe Pharma Corp., Novartis Pharma K.K.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. Y. Tanaka: research grant to the affiliated institution from AbbVie G.K., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., MSD; on the speakers’ bureau of AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Pfizer Japan Inc., Quintiles Inc., Takeda Pharmaceutical Co. Ltd. H. Yamanaka: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Nippon Kayaku Co. Ltd., Pfizer Japan Inc., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd. T. Hirose, T. Yoshinaga, and M. Suzukawa are fulltime employees of Pfizer Japan Inc. T. Koike, MD, PhD, NTT Sapporo Medical Center; M. Harigai, MD, PhD, Tokyo Medical Dental University Graduate School; S. Inokuma, MD, Japanese Red Cross Medical Center; N. Ishiguro, MD, PhD, Nagoya University Graduate School of Medicine; J. Ryu, MD, PhD, Nihon University School of Medicine; T. Takeuchi, MD, PhD, Keio University; Y. Tanaka, MD, PhD, University of Occupational and Environmental Health; H. Yamanaka, MD, PhD, Tokyo Women’s Medical University; T. Hirose, MS, Pfizer Japan Inc., Medical Affairs; T. Yoshinaga, MD, PhD, Pfizer Japan Inc., Postmarketing Surveillance; M. Suzukawa, MD, PhD, Pfizer Japan Inc., Medical Affairs. Address correspondence to Dr. T. Yoshinaga, MD, PhD, Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan. E-mail: takunari.yoshinaga@pfizer.com Accepted for publication June 6, 2013.
Tsutomu Takeuchi
From the NTT Sapporo Medical Center, Sapporo; Tokyo Medical Dental University Graduate School, Tokyo; Japanese Red Cross Medical Center, Tokyo; Nagoya University Graduate School of Medicine, Nagoya; Nihon University School of Medicine, Tokyo; Keio University, Tokyo; University of Occupational and Environmental Health, Kitakyushu; Tokyo Women’s Medical University, Tokyo; Pfizer Japan Inc., Medical Affairs, and Postmarketing Surveillance, Tokyo, Japan. Supported by Wyeth; clinical fees were shared by Wyeth K.K. and Takeda Pharmaceutical Company Ltd. T. Koike, M. Harigai, S. Inokuma, N. Ishiguro, J. Ryu, T. Takeuchi, Y. Tanaka, and H. Yamanaka are all members of the Etanercept Postmarketing Surveillance Committee of the Japan College of Rheumatology. Financial relationships of authors with all manufacturers of products used in the management of rheumatoid arthritis are as follows. T. Koike: consulting fee from UCB Japan Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Takeda Pharmaceutical Co. Ltd., Pfizer Japan Inc. M. Harigai: research grant to the affiliated institution from AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; consulting fee from AbbVie G.K., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp.; on the speakers’ bureau of AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. S. Inokuma: none. N. Ishiguro: research grant to the affiliated institution from Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. J. Ryu: none. T. Takeuchi: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Sanofi K.K., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; consulting fee from AbbVie G.K., Asahi Kasei Pharma Corp., AstraZeneca K.K., Daiichi Sankyo Co. Ltd., Eli-Lilly Japan K.K., Mitsubishi Tanabe Pharma Corp., Novartis Pharma K.K.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. Y. Tanaka: research grant to the affiliated institution from AbbVie G.K., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., MSD; on the speakers’ bureau of AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Pfizer Japan Inc., Quintiles Inc., Takeda Pharmaceutical Co. Ltd. H. Yamanaka: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Nippon Kayaku Co. Ltd., Pfizer Japan Inc., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd. T. Hirose, T. Yoshinaga, and M. Suzukawa are fulltime employees of Pfizer Japan Inc. T. Koike, MD, PhD, NTT Sapporo Medical Center; M. Harigai, MD, PhD, Tokyo Medical Dental University Graduate School; S. Inokuma, MD, Japanese Red Cross Medical Center; N. Ishiguro, MD, PhD, Nagoya University Graduate School of Medicine; J. Ryu, MD, PhD, Nihon University School of Medicine; T. Takeuchi, MD, PhD, Keio University; Y. Tanaka, MD, PhD, University of Occupational and Environmental Health; H. Yamanaka, MD, PhD, Tokyo Women’s Medical University; T. Hirose, MS, Pfizer Japan Inc., Medical Affairs; T. Yoshinaga, MD, PhD, Pfizer Japan Inc., Postmarketing Surveillance; M. Suzukawa, MD, PhD, Pfizer Japan Inc., Medical Affairs. Address correspondence to Dr. T. Yoshinaga, MD, PhD, Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan. E-mail: takunari.yoshinaga@pfizer.com Accepted for publication June 6, 2013.
Yoshiya Tanaka
From the NTT Sapporo Medical Center, Sapporo; Tokyo Medical Dental University Graduate School, Tokyo; Japanese Red Cross Medical Center, Tokyo; Nagoya University Graduate School of Medicine, Nagoya; Nihon University School of Medicine, Tokyo; Keio University, Tokyo; University of Occupational and Environmental Health, Kitakyushu; Tokyo Women’s Medical University, Tokyo; Pfizer Japan Inc., Medical Affairs, and Postmarketing Surveillance, Tokyo, Japan. Supported by Wyeth; clinical fees were shared by Wyeth K.K. and Takeda Pharmaceutical Company Ltd. T. Koike, M. Harigai, S. Inokuma, N. Ishiguro, J. Ryu, T. Takeuchi, Y. Tanaka, and H. Yamanaka are all members of the Etanercept Postmarketing Surveillance Committee of the Japan College of Rheumatology. Financial relationships of authors with all manufacturers of products used in the management of rheumatoid arthritis are as follows. T. Koike: consulting fee from UCB Japan Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Takeda Pharmaceutical Co. Ltd., Pfizer Japan Inc. M. Harigai: research grant to the affiliated institution from AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; consulting fee from AbbVie G.K., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp.; on the speakers’ bureau of AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. S. Inokuma: none. N. Ishiguro: research grant to the affiliated institution from Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. J. Ryu: none. T. Takeuchi: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Sanofi K.K., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; consulting fee from AbbVie G.K., Asahi Kasei Pharma Corp., AstraZeneca K.K., Daiichi Sankyo Co. Ltd., Eli-Lilly Japan K.K., Mitsubishi Tanabe Pharma Corp., Novartis Pharma K.K.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. Y. Tanaka: research grant to the affiliated institution from AbbVie G.K., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., MSD; on the speakers’ bureau of AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Pfizer Japan Inc., Quintiles Inc., Takeda Pharmaceutical Co. Ltd. H. Yamanaka: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Nippon Kayaku Co. Ltd., Pfizer Japan Inc., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd. T. Hirose, T. Yoshinaga, and M. Suzukawa are fulltime employees of Pfizer Japan Inc. T. Koike, MD, PhD, NTT Sapporo Medical Center; M. Harigai, MD, PhD, Tokyo Medical Dental University Graduate School; S. Inokuma, MD, Japanese Red Cross Medical Center; N. Ishiguro, MD, PhD, Nagoya University Graduate School of Medicine; J. Ryu, MD, PhD, Nihon University School of Medicine; T. Takeuchi, MD, PhD, Keio University; Y. Tanaka, MD, PhD, University of Occupational and Environmental Health; H. Yamanaka, MD, PhD, Tokyo Women’s Medical University; T. Hirose, MS, Pfizer Japan Inc., Medical Affairs; T. Yoshinaga, MD, PhD, Pfizer Japan Inc., Postmarketing Surveillance; M. Suzukawa, MD, PhD, Pfizer Japan Inc., Medical Affairs. Address correspondence to Dr. T. Yoshinaga, MD, PhD, Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan. E-mail: takunari.yoshinaga@pfizer.com Accepted for publication June 6, 2013.
Hisashi Yamanaka
From the NTT Sapporo Medical Center, Sapporo; Tokyo Medical Dental University Graduate School, Tokyo; Japanese Red Cross Medical Center, Tokyo; Nagoya University Graduate School of Medicine, Nagoya; Nihon University School of Medicine, Tokyo; Keio University, Tokyo; University of Occupational and Environmental Health, Kitakyushu; Tokyo Women’s Medical University, Tokyo; Pfizer Japan Inc., Medical Affairs, and Postmarketing Surveillance, Tokyo, Japan. Supported by Wyeth; clinical fees were shared by Wyeth K.K. and Takeda Pharmaceutical Company Ltd. T. Koike, M. Harigai, S. Inokuma, N. Ishiguro, J. Ryu, T. Takeuchi, Y. Tanaka, and H. Yamanaka are all members of the Etanercept Postmarketing Surveillance Committee of the Japan College of Rheumatology. Financial relationships of authors with all manufacturers of products used in the management of rheumatoid arthritis are as follows. T. Koike: consulting fee from UCB Japan Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Takeda Pharmaceutical Co. Ltd., Pfizer Japan Inc. M. Harigai: research grant to the affiliated institution from AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; consulting fee from AbbVie G.K., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp.; on the speakers’ bureau of AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. S. Inokuma: none. N. Ishiguro: research grant to the affiliated institution from Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. J. Ryu: none. T. Takeuchi: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Sanofi K.K., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; consulting fee from AbbVie G.K., Asahi Kasei Pharma Corp., AstraZeneca K.K., Daiichi Sankyo Co. Ltd., Eli-Lilly Japan K.K., Mitsubishi Tanabe Pharma Corp., Novartis Pharma K.K.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. Y. Tanaka: research grant to the affiliated institution from AbbVie G.K., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., MSD; on the speakers’ bureau of AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Pfizer Japan Inc., Quintiles Inc., Takeda Pharmaceutical Co. Ltd. H. Yamanaka: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Nippon Kayaku Co. Ltd., Pfizer Japan Inc., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd. T. Hirose, T. Yoshinaga, and M. Suzukawa are fulltime employees of Pfizer Japan Inc. T. Koike, MD, PhD, NTT Sapporo Medical Center; M. Harigai, MD, PhD, Tokyo Medical Dental University Graduate School; S. Inokuma, MD, Japanese Red Cross Medical Center; N. Ishiguro, MD, PhD, Nagoya University Graduate School of Medicine; J. Ryu, MD, PhD, Nihon University School of Medicine; T. Takeuchi, MD, PhD, Keio University; Y. Tanaka, MD, PhD, University of Occupational and Environmental Health; H. Yamanaka, MD, PhD, Tokyo Women’s Medical University; T. Hirose, MS, Pfizer Japan Inc., Medical Affairs; T. Yoshinaga, MD, PhD, Pfizer Japan Inc., Postmarketing Surveillance; M. Suzukawa, MD, PhD, Pfizer Japan Inc., Medical Affairs. Address correspondence to Dr. T. Yoshinaga, MD, PhD, Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan. E-mail: takunari.yoshinaga@pfizer.com Accepted for publication June 6, 2013.
Tomohiro Hirose
From the NTT Sapporo Medical Center, Sapporo; Tokyo Medical Dental University Graduate School, Tokyo; Japanese Red Cross Medical Center, Tokyo; Nagoya University Graduate School of Medicine, Nagoya; Nihon University School of Medicine, Tokyo; Keio University, Tokyo; University of Occupational and Environmental Health, Kitakyushu; Tokyo Women’s Medical University, Tokyo; Pfizer Japan Inc., Medical Affairs, and Postmarketing Surveillance, Tokyo, Japan. Supported by Wyeth; clinical fees were shared by Wyeth K.K. and Takeda Pharmaceutical Company Ltd. T. Koike, M. Harigai, S. Inokuma, N. Ishiguro, J. Ryu, T. Takeuchi, Y. Tanaka, and H. Yamanaka are all members of the Etanercept Postmarketing Surveillance Committee of the Japan College of Rheumatology. Financial relationships of authors with all manufacturers of products used in the management of rheumatoid arthritis are as follows. T. Koike: consulting fee from UCB Japan Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Takeda Pharmaceutical Co. Ltd., Pfizer Japan Inc. M. Harigai: research grant to the affiliated institution from AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; consulting fee from AbbVie G.K., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp.; on the speakers’ bureau of AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. S. Inokuma: none. N. Ishiguro: research grant to the affiliated institution from Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. J. Ryu: none. T. Takeuchi: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Sanofi K.K., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; consulting fee from AbbVie G.K., Asahi Kasei Pharma Corp., AstraZeneca K.K., Daiichi Sankyo Co. Ltd., Eli-Lilly Japan K.K., Mitsubishi Tanabe Pharma Corp., Novartis Pharma K.K.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. Y. Tanaka: research grant to the affiliated institution from AbbVie G.K., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., MSD; on the speakers’ bureau of AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Pfizer Japan Inc., Quintiles Inc., Takeda Pharmaceutical Co. Ltd. H. Yamanaka: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Nippon Kayaku Co. Ltd., Pfizer Japan Inc., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd. T. Hirose, T. Yoshinaga, and M. Suzukawa are fulltime employees of Pfizer Japan Inc. T. Koike, MD, PhD, NTT Sapporo Medical Center; M. Harigai, MD, PhD, Tokyo Medical Dental University Graduate School; S. Inokuma, MD, Japanese Red Cross Medical Center; N. Ishiguro, MD, PhD, Nagoya University Graduate School of Medicine; J. Ryu, MD, PhD, Nihon University School of Medicine; T. Takeuchi, MD, PhD, Keio University; Y. Tanaka, MD, PhD, University of Occupational and Environmental Health; H. Yamanaka, MD, PhD, Tokyo Women’s Medical University; T. Hirose, MS, Pfizer Japan Inc., Medical Affairs; T. Yoshinaga, MD, PhD, Pfizer Japan Inc., Postmarketing Surveillance; M. Suzukawa, MD, PhD, Pfizer Japan Inc., Medical Affairs. Address correspondence to Dr. T. Yoshinaga, MD, PhD, Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan. E-mail: takunari.yoshinaga@pfizer.com Accepted for publication June 6, 2013.
Takunari Yoshinaga
From the NTT Sapporo Medical Center, Sapporo; Tokyo Medical Dental University Graduate School, Tokyo; Japanese Red Cross Medical Center, Tokyo; Nagoya University Graduate School of Medicine, Nagoya; Nihon University School of Medicine, Tokyo; Keio University, Tokyo; University of Occupational and Environmental Health, Kitakyushu; Tokyo Women’s Medical University, Tokyo; Pfizer Japan Inc., Medical Affairs, and Postmarketing Surveillance, Tokyo, Japan. Supported by Wyeth; clinical fees were shared by Wyeth K.K. and Takeda Pharmaceutical Company Ltd. T. Koike, M. Harigai, S. Inokuma, N. Ishiguro, J. Ryu, T. Takeuchi, Y. Tanaka, and H. Yamanaka are all members of the Etanercept Postmarketing Surveillance Committee of the Japan College of Rheumatology. Financial relationships of authors with all manufacturers of products used in the management of rheumatoid arthritis are as follows. T. Koike: consulting fee from UCB Japan Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Takeda Pharmaceutical Co. Ltd., Pfizer Japan Inc. M. Harigai: research grant to the affiliated institution from AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; consulting fee from AbbVie G.K., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp.; on the speakers’ bureau of AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. S. Inokuma: none. N. Ishiguro: research grant to the affiliated institution from Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. J. Ryu: none. T. Takeuchi: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Sanofi K.K., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; consulting fee from AbbVie G.K., Asahi Kasei Pharma Corp., AstraZeneca K.K., Daiichi Sankyo Co. Ltd., Eli-Lilly Japan K.K., Mitsubishi Tanabe Pharma Corp., Novartis Pharma K.K.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. Y. Tanaka: research grant to the affiliated institution from AbbVie G.K., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., MSD; on the speakers’ bureau of AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Pfizer Japan Inc., Quintiles Inc., Takeda Pharmaceutical Co. Ltd. H. Yamanaka: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Nippon Kayaku Co. Ltd., Pfizer Japan Inc., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd. T. Hirose, T. Yoshinaga, and M. Suzukawa are fulltime employees of Pfizer Japan Inc. T. Koike, MD, PhD, NTT Sapporo Medical Center; M. Harigai, MD, PhD, Tokyo Medical Dental University Graduate School; S. Inokuma, MD, Japanese Red Cross Medical Center; N. Ishiguro, MD, PhD, Nagoya University Graduate School of Medicine; J. Ryu, MD, PhD, Nihon University School of Medicine; T. Takeuchi, MD, PhD, Keio University; Y. Tanaka, MD, PhD, University of Occupational and Environmental Health; H. Yamanaka, MD, PhD, Tokyo Women’s Medical University; T. Hirose, MS, Pfizer Japan Inc., Medical Affairs; T. Yoshinaga, MD, PhD, Pfizer Japan Inc., Postmarketing Surveillance; M. Suzukawa, MD, PhD, Pfizer Japan Inc., Medical Affairs. Address correspondence to Dr. T. Yoshinaga, MD, PhD, Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan. E-mail: takunari.yoshinaga@pfizer.com Accepted for publication June 6, 2013.
Michio Suzukawa
From the NTT Sapporo Medical Center, Sapporo; Tokyo Medical Dental University Graduate School, Tokyo; Japanese Red Cross Medical Center, Tokyo; Nagoya University Graduate School of Medicine, Nagoya; Nihon University School of Medicine, Tokyo; Keio University, Tokyo; University of Occupational and Environmental Health, Kitakyushu; Tokyo Women’s Medical University, Tokyo; Pfizer Japan Inc., Medical Affairs, and Postmarketing Surveillance, Tokyo, Japan. Supported by Wyeth; clinical fees were shared by Wyeth K.K. and Takeda Pharmaceutical Company Ltd. T. Koike, M. Harigai, S. Inokuma, N. Ishiguro, J. Ryu, T. Takeuchi, Y. Tanaka, and H. Yamanaka are all members of the Etanercept Postmarketing Surveillance Committee of the Japan College of Rheumatology. Financial relationships of authors with all manufacturers of products used in the management of rheumatoid arthritis are as follows. T. Koike: consulting fee from UCB Japan Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Takeda Pharmaceutical Co. Ltd., Pfizer Japan Inc. M. Harigai: research grant to the affiliated institution from AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; consulting fee from AbbVie G.K., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp.; on the speakers’ bureau of AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. S. Inokuma: none. N. Ishiguro: research grant to the affiliated institution from Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. J. Ryu: none. T. Takeuchi: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Sanofi K.K., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; consulting fee from AbbVie G.K., Asahi Kasei Pharma Corp., AstraZeneca K.K., Daiichi Sankyo Co. Ltd., Eli-Lilly Japan K.K., Mitsubishi Tanabe Pharma Corp., Novartis Pharma K.K.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. Y. Tanaka: research grant to the affiliated institution from AbbVie G.K., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., MSD; on the speakers’ bureau of AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Pfizer Japan Inc., Quintiles Inc., Takeda Pharmaceutical Co. Ltd. H. Yamanaka: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Nippon Kayaku Co. Ltd., Pfizer Japan Inc., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd. T. Hirose, T. Yoshinaga, and M. Suzukawa are fulltime employees of Pfizer Japan Inc. T. Koike, MD, PhD, NTT Sapporo Medical Center; M. Harigai, MD, PhD, Tokyo Medical Dental University Graduate School; S. Inokuma, MD, Japanese Red Cross Medical Center; N. Ishiguro, MD, PhD, Nagoya University Graduate School of Medicine; J. Ryu, MD, PhD, Nihon University School of Medicine; T. Takeuchi, MD, PhD, Keio University; Y. Tanaka, MD, PhD, University of Occupational and Environmental Health; H. Yamanaka, MD, PhD, Tokyo Women’s Medical University; T. Hirose, MS, Pfizer Japan Inc., Medical Affairs; T. Yoshinaga, MD, PhD, Pfizer Japan Inc., Postmarketing Surveillance; M. Suzukawa, MD, PhD, Pfizer Japan Inc., Medical Affairs. Address correspondence to Dr. T. Yoshinaga, MD, PhD, Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan. E-mail: takunari.yoshinaga@pfizer.com Accepted for publication June 6, 2013.
Article Information
jrheum.120490
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online August 1, 2013.
Article Versions
- You are currently viewing a Latest version of this article (August 1, 2013 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2013 The Journal of Rheumatology
Author Information
- Takao Koike,
- Masayoshi Harigai,
- Shigeko Inokuma,
- Naoki Ishiguro,
- Junnosuke Ryu,
- Tsutomu Takeuchi,
- Yoshiya Tanaka,
- Hisashi Yamanaka,
- Tomohiro Hirose,
- Takunari Yoshinaga and
- Michio Suzukawa
- From the NTT Sapporo Medical Center, Sapporo; Tokyo Medical Dental University Graduate School, Tokyo; Japanese Red Cross Medical Center, Tokyo; Nagoya University Graduate School of Medicine, Nagoya; Nihon University School of Medicine, Tokyo; Keio University, Tokyo; University of Occupational and Environmental Health, Kitakyushu; Tokyo Women’s Medical University, Tokyo; Pfizer Japan Inc., Medical Affairs, and Postmarketing Surveillance, Tokyo, Japan.
Supported by Wyeth; clinical fees were shared by Wyeth K.K. and Takeda Pharmaceutical Company Ltd. T. Koike, M. Harigai, S. Inokuma, N. Ishiguro, J. Ryu, T. Takeuchi, Y. Tanaka, and H. Yamanaka are all members of the Etanercept Postmarketing Surveillance Committee of the Japan College of Rheumatology. Financial relationships of authors with all manufacturers of products used in the management of rheumatoid arthritis are as follows. T. Koike: consulting fee from UCB Japan Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Takeda Pharmaceutical Co. Ltd., Pfizer Japan Inc. M. Harigai: research grant to the affiliated institution from AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co.
Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; consulting fee from AbbVie G.K., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp.; on the speakers’ bureau of AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. S. Inokuma: none. N. Ishiguro: research grant to the affiliated institution from Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. J. Ryu: none. T. Takeuchi: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Sanofi K.K., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; consulting fee from AbbVie G.K., Asahi Kasei Pharma Corp., AstraZeneca K.K., Daiichi Sankyo Co. Ltd., Eli-Lilly Japan K.K., Mitsubishi Tanabe Pharma Corp., Novartis Pharma K.K.; on the speakers’ bureau of Abbott Japan Co. Ltd., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co.
Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. Y. Tanaka: research grant to the affiliated institution from AbbVie G.K., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., MSD; on the speakers’ bureau of AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co.
Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Pfizer Japan Inc., Quintiles Inc., Takeda Pharmaceutical Co. Ltd. H. Yamanaka: research grant to the affiliated institution from AbbVie G.K., Abbott Japan Co. Ltd., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., MSD, Nippon Kayaku Co. Ltd., Pfizer Japan Inc., Santen Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; on the speakers’ bureau of Abbott Japan Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd. T. Hirose, T. Yoshinaga, and M. Suzukawa are fulltime employees of Pfizer Japan Inc.
T. Koike, MD, PhD, NTT Sapporo Medical Center; M. Harigai, MD, PhD, Tokyo Medical Dental University Graduate School; S. Inokuma, MD, Japanese Red Cross Medical Center; N. Ishiguro, MD, PhD, Nagoya University Graduate School of Medicine; J. Ryu, MD, PhD, Nihon University School of Medicine; T. Takeuchi, MD, PhD, Keio University; Y. Tanaka, MD, PhD, University of Occupational and Environmental Health; H. Yamanaka, MD, PhD, Tokyo Women’s Medical University; T.
Hirose, MS, Pfizer Japan Inc., Medical Affairs; T. Yoshinaga, MD, PhD, Pfizer Japan Inc., Postmarketing Surveillance; M. Suzukawa, MD, PhD, Pfizer Japan Inc., Medical Affairs.
Address correspondence to Dr. T. Yoshinaga, MD, PhD, Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan.
E-mail: takunari.yoshinaga@pfizer.com
Accepted for publication June 6, 2013.
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Safety and Effectiveness of 6 Months' Etanercept Monotherapy and Combination Therapy in Japanese Patients with Rheumatoid Arthritis: Effect of Concomitant Disease-modifying Antirheumatic Drugs
Takao Koike, Masayoshi Harigai, Shigeko Inokuma, Naoki Ishiguro, Junnosuke Ryu, Tsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka, Tomohiro Hirose, Takunari Yoshinaga, Michio Suzukawa
The Journal of Rheumatology Aug 2013, jrheum.120490; DOI: 10.3899/jrheum.120490
Safety and Effectiveness of 6 Months' Etanercept Monotherapy and Combination Therapy in Japanese Patients with Rheumatoid Arthritis: Effect of Concomitant Disease-modifying Antirheumatic Drugs
Takao Koike, Masayoshi Harigai, Shigeko Inokuma, Naoki Ishiguro, Junnosuke Ryu, Tsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka, Tomohiro Hirose, Takunari Yoshinaga, Michio Suzukawa
The Journal of Rheumatology Aug 2013, jrheum.120490; DOI: 10.3899/jrheum.120490